5-aminosalicylic acid not linked to renal impairment in IBD

  • Jairath V & al.
  • Aliment Pharmacol Ther
  • 12 Jul 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Oral 5‐aminosalicylate acid (5‐ASA) anti-inflammatory drugs are not associated with renal impairment in patients with ulcerative colitis (UC) or Crohn's disease (CD).

Why this matters

  • Previous studies have offered conflicting evidence about nephrotoxicity associated with 5-ASAs.

Study design

  • Researchers studied anonymised medical records of 35,601 patients with UC or CD from a large primary care database.
  • Funding: Takeda Pharmaceutical Company.

Key results

  • The nephrotoxicity incidence rate was similar and stable for patients with either UC (12.6 per 1000 person‐years) or CD (10.9 per 1000 person‐years).
  • 5-ASA was not associated with nephrotoxicity either in patients with prescriptions ≤30 days or 31 to ≤180 days before index:
    • UC: OR, 1.05 (95% CI, 0.86‐1.28).
    • CD: OR, 1.22 (95% CI, 0.91‐1.62).
  • Factors independently associated with renal impairment in both UC and CD included disease duration, cardiovascular disease, diabetes mellitus, and nephrotoxic drug use.

Limitations

  • Study data counted prescriptions issued rather than dispensed.
  • The study was retrospective and did not establish causality.